Treatment & Research Archives

June 18, 2025

Outcomes After Discontinuing BTKi Due to Adverse Effects

Patients with CLL who have to discontinue a BTK inhibitor due to adverse side effects can still experience prolonged remissions without therapy.

June 18, 2025

Rocbrutinib – a Dual Covalent and Non-Covalent BTK Inhibitor

Though it is still early on, rocbrutinib appears to be effective in CLL patients with prior BTKi resistance mutations, and it is generally well-tolerated.

June 18, 2025

Reducing Tumor Lysis Syndrome Risk with Venetoclax in CLL

The risk of dangerous tumor lysis syndrome, when venetoclax is started, has limited its use in the community.

June 9, 2025

MRD-Guided Ibrutinib Plus Venetoclax Therapy for CLL

MRD-guided ibrutinib plus venetoclax is a very effective combination therapy for treating CLL, and it can provide durable responses.

June 9, 2025

Ibrutinib Improves Life Expectancy in Patients with CLL

Patients with CLL treated with ibrutinib have a 9-year overall survival rate, irrespective of high-risk features.

May 28, 2025

Duvelisib Plus Venetoclax for Relapsed CLL

The time-limited combination of duvelisib plus venetoclax was effective for treating relapsed / refractory CLL, but it also had significant side effects.

May 28, 2025

CAR-T Offers Excellent Results in CLL and Richter’s Syndrome

By never freezing the locally produced CAR-T cells, disappointing response rates for relapsed/refractory CLL and Richter’s Syndrome patients are greatly improved

May 28, 2025

Long-Term Outcomes After CAR-T Therapy for CLL

CAR-T therapy can provide very long remissions in a subset of patients with relapsed / refractory CLL who responded for at least one year.

May 28, 2025

A Noncovalent LYN / BTK Dual Inhibitor for Relapsed B Cell Cancers

DZD8586 is an experimental noncovalent LYN / BTK dual inhibitor that is being tested in patients with relapsed / refractory B cell cancers.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Treatment & Research

Outcomes After Discontinuing BTKi Due to Adverse Effects

Rocbrutinib – a Dual Covalent and Non-Covalent BTK Inhibitor

Reducing Tumor Lysis Syndrome Risk with Venetoclax in CLL

MRD-Guided Ibrutinib Plus Venetoclax Therapy for CLL

Ibrutinib Improves Life Expectancy in Patients with CLL

Duvelisib Plus Venetoclax for Relapsed CLL

CAR-T Offers Excellent Results in CLL and Richter’s Syndrome

Long-Term Outcomes After CAR-T Therapy for CLL

A Noncovalent LYN / BTK Dual Inhibitor for Relapsed B Cell Cancers

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT